Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
GlobeNewswire
The Worldwide Market for Point-of-Care (POC) Diagnostic Tests 2022: Skyrocketing Demand For Accurate and Easy Testing Fueling Growth
Research and Markets
4 min read
Company Logo
Company Logo

Dublin, July 22, 2022 (GLOBE NEWSWIRE) -- The "The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition" report has been added to ResearchAndMarkets.com's offering.

As discussed in this report, The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition, POC testing has skyrocketed in the last 20 years as demand for accurate and rapid testing has blossomed both inside and outside the hospital setting.

Emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are influencing the POC landscape. The driving force behind these innovations in the health arena is to provide expedited diagnosis where the patient is seen or in the patient's home. The POC diagnostic industry will be part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine.

POC tests are performed in a wide range of geographical locations such as:

  • Hospital departments such as emergency departments, operating rooms, intensive care units, and others

  • Physicians' offices

  • Hospital clinics

  • Rural health clinics

  • Student health clinics

  • Retail clinics

  • Pharmacies

  • Homes - With testing performed by patients, visiting nurses, or other caregivers

  • Nursing homes

  • Prisons

The menu for point-of-care testing continues to expand. The traditional set of POC tests includes blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, hemoglobin diagnostics, infectious disease testing and cholesterol screening.

Moreover, POC test devices have contributed significantly to the growth of the overall diagnostics market over the past 10 years. More diagnostic manufacturers have pursued CLIA waiver status for their POC devices and CE Mark for POC or self-use. At the same time, more decentralized test venues invest in non-waived rapid tests and instruments.

POC testing appears to be headed for an even bigger role in diagnosis and monitoring patient care. New technologies are allowing POC devices to produce quantitative lab-quality test results that can be transferred automatically to an information system, a remote caregiver service for consultation or an electronic medical record. Rapid tests are beginning to fold into the point of care arena because they allow the physician to treat the patient before they leave the clinic or office.

Among the top and/or innovative competitors discussed within Corporate Profiles are:

  • 1 Step Detect Associates

  • Abbott Laboratories

  • Abingdon Health

  • Access Bio

  • AccuBioTech Co

  • ACON Laboratories

  • Aerscher Diagnostics

  • Akers Biosciences

  • Alfa Scientific Designs

  • American Bio Medica

  • ARKRAY

  • Artron Laboratories

  • Ascensia Diabetes Care

  • Ativa Medical Corp

  • Atlas Link Biotech

  • Audit Diagnostics

  • Autobio Diagnostics

  • Beckman Coulter

  • Becton Dickinson

  • Beijing Wantai Biological Pharmaceuticals

  • Bhat Bio-Tech India Private Ltd.

  • Binx health

  • bioLytical Laboratories

  • BioMedomics

  • Biomeme

  • Biomerica

  • bioMerieux SA

  • Bio-Rad Laboratories

  • Biosensia

  • Biotron Diagnostics

  • Boditech Med

  • Boson Biotech

  • BTNX

  • Calypte Biomedical Corp

  • Cepheid

  • Chembio Diagnostics

  • Church & Dwight

  • Clarity Diagnostics

  • Confirm Biosciences

  • CTK Biotech

  • Danaher Corporation

  • Dexcom

  • DIALAB

  • DiaSys Diagnostic Systems

  • Diazyme Laboratories

  • DNA Electronics Ltd. (DNAe)

  • Dr Fooke-Achterrath

  • DxGen

  • Eiken Chemical

  • EKF Diagnostics

  • ELITechGroup, Inc

  • Enterix (Clinical Genomics)

  • Eurobio Scientific

  • Everlywell

  • Exact Sciences

  • EY Laboratories

  • First Check Diagnostics

  • GenBio

  • Genedrive

  • GenePOC

  • GeTein Biotech Inc.

  • GlysBy

  • Helena Labs

  • Hemosure

  • HORIBA

  • Immunosciences Lab

  • Immunostics

  • Mitra & Co Pvt

  • JAL Innovation

  • Jant Pharmacal

  • LamdaGen Corp

  • LifeScan

  • LifeSign

  • LightDeck Diagnostics

  • Macherey-Nagel

  • Medix Biochemica

  • MedMira

  • Medtronic

  • Menarini Diagnostics

  • Meridian BioScience

  • MiCo BioMed USA

  • Nano-Ditech Corporation

  • NG Biotech

  • Noble Medical

  • Nova Biomedical

  • NuGenerex Diagnostics

  • Oasis Diagnostics

  • Operon

  • OPKO Health

  • OraSure Technologies

  • Polymedco

  • Polymer Technologies (PTS Diagnostics)

  • Preventis

  • Princeton Biomeditech

  • QuantuMDx Group

  • Quidel

  • Radiometer Medical

  • Randox Labs

  • RENESA UG

  • Response Biomedical

  • Reszon Diagnostics

  • Rheonix

  • Roche Diagnostics

  • Savyon Diagnostics

  • Sekisui Diagnostics

  • Siemens Healthcare

  • Sysmex

  • TECHLAB

  • Trinity Biotech

  • Trividia Health

  • Tulip Diagnostics

  • VedaLab

  • Veredus Laboratories

  • Werfen

Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice
More Info

Recommended Stories